For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome.
|Sample type||Average %||Range|
|Plasma||94.8||% - %|
Abcam’s Complement C3a des Arg Human in vitro competitive ELISA (Enzyme-Linked Immunosorbent Assay) kit is for the accurate quantitation of Human Complement C3a des Arg in plasma.
A goat anti-rabbit IgG antibody has been precoated onto 96-well plates. Standards or test samples are added to the wells, along with an alkaline phosphatase (AP) conjugated-Complement C3a des Arg antigen and a polyclonal rabbit antibody specific to Complement C3a des Arg. After incubation the excess reagents are washed away. pNpp substrate is added and after a short incubation the enzyme reaction is stopped and the yellow color generated is read at 405 nm. The intensity of the yellow coloration is inversely proportional to the amount of Complement C3a des Arg captured in the plate.
The Human C3a des Arg molecule is one of three activation fragments formed from the activation of the complement cascade. C3a des Arg is formed from C3a via carboxypeptidase cleavage of the C-terminal arginine group. The structure of Human C3a des Arg was first reported in 1975 by Hugli. Human C3a des Arg contains 77 amino acids with 6 cysteines involved in disulfide bridges between residues 22-49, 23-56 and 36-57. The C terminal end of C3a des Arg in Human, porcine, rat, mouse and guinea pig is identical. C3a des Arg is a highly cationic molecule containing no carbohydrate. X-ray crystal data shows the N and C terminal residues to have highly flexible helical structures. C3a is one of the most potent constrictors of smooth muscle cells, and guinea pig airways are hyperresponsive to C3a when pretreated with histamine. The long term study of liver and other transplant recipients for both C3a des Arg and C4a des Arg may be useful in assessing a number of pathological conditions. The use of potent protease inhibitors, such as Futhan, in conjunction with EDTA, may allow complement activation factors to be quantitated specifically via inhibition of non-specific protease formation of C3a des Arg.
Human Complement C3a des Arg
Human Complement C3
Human Complement C4a des Arg
|Human Complement C4||0.31%|
Human Complement C5 des Arg
|Human Complement C5||0.05%|
|Components||1 x 96 tests|
|20X Wash Buffer Concentrate||1 x 30ml|
|Assay Buffer 10 Concentrate||1 x 15ml|
|Complement Reagent A||1 x 15ml|
|Complement Reagent B||1 x 30ml|
|Goat anti-rabbit IgG Microplate (12 x 8 wells)||1 unit|
|Human Complement C3a des Arg EIA Antibody||1 x 6ml|
|Human Complement C3a des Arg EIA Conjugate||1 x 6ml|
|Human Complement C3a des Arg Standard||2 x 500ng|
|Plate Sealer||2 units|
|pNpp Substrate||1 x 23ml|
|Stop Solution||1 x 6ml|
Our Abpromise guarantee covers the use of ab133037 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Competitive ELISA||Use at an assay dependent concentration.|
ab133037 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"